An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6 [10]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 442-444

  Bonnet Brilhault, Frédérique ^a,b,c   Broly, Frank ^d   Blanc, Romuald ^a,b   Furet, Yves ^b   Barthélémy, Catherine ^a,b,c   Paintaud, Gilles ^b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CARBOXYLESTERASE; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; DNA; HYDROXYZINE; IMIPRAMINE; METHYLPHENIDATE; THIORIDAZINE;

ATTENTION DEFICIT DISORDER; CASE REPORT; CAUCASIAN; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG URINE LEVEL; ENZYME ACTIVITY; FAMILY HISTORY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; HYPERTENSION; INDIVIDUALIZATION; INTRON; LETTER; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHYLPHENIDATE; TIME FACTORS;

EID: 33746899642     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000227352.52288.50     Document Type: Letter

References (16)

1. Birmaher B, Khetarpal S, Brent D, et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry. 1997;36:545-553.
2. Poznanski EO, Freeman LN, Mokros HB. Children' depression rating scale-revised. Psychopharmacol Bull. 1985;21:979-989.
3. Conners CK, Sitarenios G, Parker JD, et al. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26:257-268.
4. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002;12(6):465-472.
5. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995;5(4):215-223.
6. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392(1):30-34.
7. Chida M, Yokoi T, Fukui T, et al. Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res. 1999;90(9):899-902.
8. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419-15422.
9. Morin S, Loriot MA, Poirier JM, et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol. 2001;56(11):793-797.
10. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem. 2003;49:542-551.
11. Llerena A, Edman G, Cobaleda J, et al. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand. 1993;87(1):23-28.
12. DeVane CL, Markowitz JS, Carson SW, et al. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol. 2000;20(3): 347-349.
13. Srinivas NR, Hubbard JW, McKay G, et al. In vitro hydrolysis of RR,SS-threo-methylphenidate by blood esterases - differential and enantioselective interspecies variability. Chirality. 1991;3(2):99-103.
14. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet. 2001;40(10):753-772.
15. de Leon J, Barnhil J, Rogers T, et al. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry. 1998;155(9):1278-1280.
16. Laine K, Tybring G, Hartter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001;70(4):327-335.